Scholarlink

<p>Semaglutide, a GLP-1 receptor agonist, improves metabolic health and reduces liver fat in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). This post hoc analysis of the 24-week SLIM LIVER single-arm trial (ACTG A5371, No. NCT04216589, registered 02nd Jan 2020) in 41 PWH with MASLD receiving semaglutide (1.0 mg weekly) aimed to evaluate its effect on epigenetic aging and determine whether changes in epigenetic clocks associate with clinical responsiveness. Over 24 weeks, we observed DunedinPACE median change +0.018 (IQR –0.023 to +0.053), PCDNAmTL –0.006 kb (IQR –0.073 to +0.054), and PCGrimAge +0.54 years (IQR –0.33 to +1.26). Participants with decreased DunedinPACE (41.5%) showed greater liver fat reduction (<i>p</i> = 0.024) and trend towards improved gait speed (<i>p</i> = 0.081). Increased PCDNAmTL was associated with better gait speed (<i>p</i> = 0.012). These data suggest early signals of semaglutide responsiveness and relationships to epigenetic age biomarkers. Epigenetic biomarkers may enhance precision in GLP-1RA therapy and enable noninvasive monitoring of biological aging. Trial Registration: ClinicalTrials.gov ID: NCT04216589, registered 02nd Jan 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Michael J. Corley,
  • Alina P. S. Pang,
  • Douglas W. Kitch,
  • Amy Kantor,
  • Fred Sattler,
  • Pablo F. Belaunzaran-Zamudio,
  • Todd T. Brown,
  • Alan Landay,
  • Jordan E. Lake,
  • Kristine M. Erlandson

摘要

Semaglutide, a GLP-1 receptor agonist, improves metabolic health and reduces liver fat in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). This post hoc analysis of the 24-week SLIM LIVER single-arm trial (ACTG A5371, No. NCT04216589, registered 02nd Jan 2020) in 41 PWH with MASLD receiving semaglutide (1.0 mg weekly) aimed to evaluate its effect on epigenetic aging and determine whether changes in epigenetic clocks associate with clinical responsiveness. Over 24 weeks, we observed DunedinPACE median change +0.018 (IQR –0.023 to +0.053), PCDNAmTL –0.006 kb (IQR –0.073 to +0.054), and PCGrimAge +0.54 years (IQR –0.33 to +1.26). Participants with decreased DunedinPACE (41.5%) showed greater liver fat reduction (p = 0.024) and trend towards improved gait speed (p = 0.081). Increased PCDNAmTL was associated with better gait speed (p = 0.012). These data suggest early signals of semaglutide responsiveness and relationships to epigenetic age biomarkers. Epigenetic biomarkers may enhance precision in GLP-1RA therapy and enable noninvasive monitoring of biological aging. Trial Registration: ClinicalTrials.gov ID: NCT04216589, registered 02nd Jan 2020.